References
- Mey U, et al. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003;4(2):86–94.
- Berman E, et al. Incidence of response and long-term follow-up in patients with hairy cell leukaemia treated with recombinant interferon alfa-2a. Blood 1990;75 (4):839–845.
- Zinzani PL, et al. Hairy-cell leukaemia and alpha-interferon treatment: Long-term responders. Haematologica 1997; 82(2):152–155.
- Ho AD, et al. Response to pentostatin in hairy-cell leukaemia refractory to interferon-alpha. The European organization for research and treatment of cancer leukaemia cooperative group. J Chin Oncol 1989;7(10):1533–1538.
- Johnston JB, et al. Efficacy of 2′-deoxycoformycin in hairy-cell leukaemia: A study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1988;80(10): 765–769.
- Saven A, Piro LD. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia. Cancer Invest 1993;11(5):559–564.
- Goodman GR, Beutler E, Saven A. Cladribine in the treatment of hairy-cell leukaemia. Best Pract Res Chin Haematol 2003;16(1):101–116.
- Goodman GR, et al. Extended follow-up of patients with hairy cell leukaemia after treatment with cladribine. J Chin Oncol 2003;21(5):891–896.
- Lauria F, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia. Haematologica 2001;86(10):1046–1050.
- Thomas DA, et al. Rituximab in relapsed or refractory hairy cell leukaemia. Blood 2003;102 (12):3906–3911.
- Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia. Blood 2003;102(3):810–813.
- Kreitman RJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukaemia. N Engl J Med 2001;345(4):241–247.
- Hagberg H, Lundholm L. Ritwdmab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115(3):609–611.